NEJM:奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌

2019-12-19 MedSci MedSci原创

奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌效果显著

奥拉帕尼对新近诊断为晚期卵巢癌并伴有BRCA突变患者的维持治疗具有重要的临床价值。近日研究人员考察了奥拉帕尼联合贝伐单抗对全部卵巢癌患者的疗效。

诊断的、晚期、高级别卵巢癌患者参与研究,在一线铂-紫杉烷化疗加贝伐单抗治疗后有反应。无论手术结果或BRCA突变情况,患者随机接受奥拉帕尼(每日两次,300毫克)或安慰剂,持续24个月;所有患者每3周服用一次贝伐单抗,剂量为每公斤15毫克,共15个月。研究的主要终点为疾病进展或死亡。

806名患者中,537名患者接受了奥拉帕尼治疗,269名患者接受了安慰剂治疗。中位随访22.9个月后,奥拉帕尼+贝伐单抗的中位无进展生存期为22.1个月,安慰剂+贝伐单抗的中位无进展生存期为16.6个月(疾病进展或死亡的危险比为0.59)。同源重组缺陷阳性(HRD)的肿瘤患者中,奥拉帕尼组vs.安慰剂组疾病进展或死亡危险比为0.33,在BRCA突变的肿瘤,中位无进展生存期分别为37.2 vs.17.7个月,无BRCA突变的HRD阳性肿瘤患者的中位无进展生存期分别为,28.1vs.16.6个月,疾病进展或死亡危险比为0.43。

研究认为,奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌效果显著。

原始出处:

Isabelle Ray-Coquard et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med, December 19, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>,绝佳搭配! 不过,<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>,估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
    2020-11-09 lovetcm

    #奥拉帕利#联合#贝伐单抗#,绝佳搭配! 不过,#尼拉帕利#如果联合贝伐单抗或#安罗替尼#,估计效果也不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>,绝佳搭配! 不过,<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>,估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>,绝佳搭配! 不过,<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>,估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>,绝佳搭配! 不过,<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>,估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
    2019-12-19 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

解读PRIMA研究: 卵巢癌一线维持治疗突破限制,进入2.0全人群时代

卵巢癌早诊难、分期晚、易复发,一直是妇科肿瘤治疗的难题。PARP抑制剂的出现打破了卵巢癌反复复发的治疗困局。PARP抑制剂的研发是基于BRCA基因突变产生的“合成致死效应”,因而最初的研究设计和临床应用限于BRCA突变患者,而这部分仅占卵巢癌的20%~25%,一线维持治疗需求仍未被满足。

Clin Cancer Res:靶向卵巢纤维化预防卵巢癌,神药二甲双胍从未让我们失望!

在刚刚举行的ESMO 2019 年会上,尼拉帕利作为维持卵巢癌的一线治疗再次取得了优异的成绩,临床试验中显示出了广谱的抗癌效果。与此同时,渥太华大学Barbara Vanderhyden博士的实验室对卵巢癌的研究也取得了新突破:卵巢纤维化作为卵巢癌的独立危险因素而存在,而神药二甲双胍竟可有效阻止这一过程,这无疑是卵巢癌研究的历史长河中浓墨重彩的一笔,卵巢癌患者的春天似乎要来了!

卵巢癌患者基因检测策略

ESMO发布的Ⅲ期临床试验PAOLA-1研究的数据不仅证实了PARP抑制剂(PARP inhibitor,PARPi)奥拉帕利联合贝伐珠单抗的方案可用于卵巢癌患者一线维持治疗,两个预先指定的亚组分析[分别基于BRCAm状态和同源重组缺陷(homologous recombination deficiency,HRD)状态]的阳性结果将一个稍许陌生的名词 “HRD”带入大家的关注范围。为此,我们将通

阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗

阿斯利康及其营销合作MSD(默克)已将其PARP抑制剂Lynparza(olaparib)作为卵巢癌的一线治疗药物在中国获得了销售授权,用于新诊断的晚期或体细胞BRCA突变的卵巢癌、输卵管癌或原发性腹膜癌的妇女,这些妇女对一线铂类化学疗法完全或部分反应。

NEJM:Niraparib一线治疗晚期卵巢癌

在新诊断的晚期卵巢癌患者中,Niraparib治疗可显著延长无进展生存期

乳腺癌及卵巢癌诊疗一体化中心全国启动,全面助力女性肿瘤规范化诊疗

11月30日,乳腺癌及卵巢癌诊疗一体化中心在首届阿斯利康女性肿高峰瘤论坛正式启动,该项目旨在为我国乳腺癌、卵巢癌患者提供从筛查、诊断、治疗、随访一体化的全病程诊疗方案,助力提升我国女性肿瘤总体诊疗水平。 乳腺癌、卵巢癌严重危害女性健康  规范化诊疗任重道远 作为最常见的妇科恶性肿瘤,乳腺癌、卵巢癌严重威胁我国女性身心健康。国家癌症中心发布的《2019全国癌症报告》中显示,我国乳腺癌发